# Attune Neurosciences, Inc.

> Attune Neurosciences is a San Francisco-based, clinical-stage medical device company building what it calls the first wearable, non-invasive focused-ultrasound system for deep brain therapy. Its investigational headband, ATTN201, uses low-intensity transcranial focused ultrasound (tFUS) to reach precise deep-brain targets - like the central medial thalamus - while recording EEG and head movement, aiming to treat sleep and wake disorders, depression, addiction recovery, and other neurological and psychiatric conditions without drugs or surgery.

- **Founded:** 2019
- **Headquarters:** San Francisco, California, United States
- **Founders:** Rajiv Mahadevan (Co-Founder & CEO), Luis de Lecea (Co-Founder & Senior Scientific Advisor), Keith Murphy (Co-Founder), Pablo Villoslada (Co-Founder, Clinical Development)
- **Team size:** ~15 employees
- **Products:** ATTN201, Focused ultrasound neuromodulation platform, Preclinical / research tools
- **Notable:** Developing what it describes as the first wearable, non-invasive focused-ultrasound system for deep brain therapy., Advanced ATTN201 into human clinical trials, including a central medial thalamus safety study (NCT05895474)., Published feasibility research on wearing a neuromodulation device overnight in individuals recovering from opioid use disorder (PubMed 39676914).

## Products & services

- **ATTN201** — An investigational wearable headband that delivers low-intensity transcranial focused ultrasound (tFUS) to deep brain targets while recording EEG and head movement via on-device electrodes and accelerometry. Being studied for sleep induction, depression, addiction recovery and other neurological and psychiatric conditions.
- **Focused ultrasound neuromodulation platform** — A closed-loop, MRI-guided, adaptive focused-ultrasound system combining transducer innovation, targeting algorithms and adaptive positioning to reach deep brain structures such as the central medial thalamus non-invasively.
- **Preclinical / research tools** — High-throughput ultrasound neuromodulation platforms used in awake, freely behaving animal research to advance neuroscience and validate stimulation protocols.

## Achievements

- Developing what it describes as the first wearable, non-invasive focused-ultrasound system for deep brain therapy.
- Advanced ATTN201 into human clinical trials, including a central medial thalamus safety study (NCT05895474).
- Published feasibility research on wearing a neuromodulation device overnight in individuals recovering from opioid use disorder (PubMed 39676914).
- Assembled research collaborations spanning DARPA, NIH, USSOCOM, UCSF and One Mind.
- Holds multiple patents for wearable transcranial dual-mode ultrasound transducers.
- Runs the FUS Forward podcast, one of the most extensive interview series on the focused-ultrasound field.

## Latest updates

- **2025-10** — Preprint posted on a wearable focused-ultrasound neuromodulation and electrophysiological recording patch for REM sleep enhancement (bioRxiv).
- **2025-01** — Reported an additional grant funding round supporting continued clinical development.
- **2024-12** — Published feasibility and acceptability findings for overnight neuromodulation-device use in opioid-use-disorder recovery.
- **2023-05** — Registered clinical trial studying transcranial focused ultrasound safety at the central medial thalamus (NCT05895474).

## Links

- Website: https://attuneneuro.com
- LinkedIn: https://www.linkedin.com/company/attune-neurosciences/

---

Profile page: https://yespress.io/attune-neurosciences-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-07